Wenzhi Tian

Founder and CEO at ImmuneOnco

Speaker

Dr. Wenzhi Tian, is a renowned expert in cancer immunotherapies with over 30 years of academic and industrial experience in the field of immuno-oncology. Dr. Wenzhi Tian is the Founder, Chairman and Chief Executive Officer of ImmuneOnco Biopharma. Prior to founding our Company in 2015, Dr. Tian co-founded and managed Huabo Biopharm and served as the principal research scientist at ImClone Systems. Before devoting himself to the pharmaceutical industry, Dr. Tian spent close to 15 years conducting academic research specifically on immunology at various research institutes, including Karolinska Institute in

Sweden, Weill Medical College of Cornell University and North Shore University Hospital in the United States. With extensive expertise in cancer immunology, Dr. Tian taught as adjunct professor at Fudan University, Zhengzhou University and Henan University. Based on his in- depth understanding of cancer immunology, Dr. Tian has been at the forefront of scientific research and built a proven track record in target validation, molecule design and drug development for innovative immunotherapies. He identified CD47 as a promising immunotherapeutic target and commenced drug research on CD47 starting from 2010, roughly 10 years earlier than the validation of CD47 by clinical data. His deep expertise and foresight in target selection led to our development of multiple monoclonal antibody and bispecific molecules targeting CD24, another promising checkpoint since 2019, all with global first-in-class potential. A prolific scientist, Dr. Tian invented 12 issued patents and 44 patent applications, and published over 30 scientific